November 14-16, 2017
Boston, MA

4 Weeks To Go! Register Here 

LinkedIn Icon

Day One
Wednesday, November 15, 2017

Day Two
Thursday, November 16, 2017

Breakfast & Registration

Chair’s Opening Remarks

Ensuring Successful Delivery of Neoantigen Therapies

How to Create Better Prediction of Neoantigens


  • Algorithms vs. Experimental Assays
  • How can we translate these neoantigens to the clinic?
  • How can bioinformatics approaches improve prediction?
  • Effect of mutational burden on identification and validation of neoantigens

Vaccination with Great Ape Derived Adenovectors Encoding for Cancer Neoantigens Shows Potent Synergy with Immunomodulators


  • Adenoviral vectors can encode a large number of neoantigens
  • Vaccination with Adenovectors encoding for cancer neoantigens induce a powerful T cell response against neoantigens in mice bearing large tumors
  • Different levels of efficacy can be raised by vaccination according to selection of the immunomodulator for the combo

Neoantigens are the Achilles’ Heel of Cancer


  • T cells can be genetically modified to target neoantigens
  • T-cell therapy can be generated to target solid tumors

Morning Refreshments & Networking

Clinical Trials Case Studies


Hear updates on the most advanced clinical programs to discover how the application of neoantigen targets are being successfully utilised in therapeutic individualized approaches.

Targeting Patient-Specific Neoantigens using a Personalized, Live-Attenuated Double Deleted Listeria monocytogenes (pLADD) Immunotherapy


  • Personalized medicine treatment approach by targeting patient-specific neoantigens
  • Rationale and preclinical and clinical data supporting the development of pLADD immunotherapy
  • pLADD clinical development strategy and update will be discussed

Exploiting NGS for Clinical Individualized Neoantigen Cancer Vaccines

  • John Castle Executive Director, Translational Medicine , Agenus


  • Treating cancer patients with individualized vaccines manufactured on-demand based on a NGS-profile of the patient tumor
  • Exploiting NGS, bioinformatics, and computational immunology to generate the patientspecific vaccine blueprint
  • Initial clinical data for our second-generation neoantigen vaccine platform, AutoSynVax™ (ASV™), that encodes mutation-containing peptides in a proprietary formulation and clinically tested adjuvant

Synthetic Long Peptides for Neoantigen-Specific Immunotherapy of Cancer:


ISA101 Trial Updates
· Clinical results including correlates with immuneresponses from trials with ISA101 in HPV16 induced cancers
· Discuss performance and approach of ISA proprietary bioinformatics pipeline ISABELLA in calling neoantigens
· Discuss ISA’s cGMP pSLP manufacturing capabilities (timelines, capacity, cost estimates) and formulation expertise


Lunch Networking

Turning Up the Heat on Pancreatic Cancer: Overcoming an Immunologically Cold Landscape

  • Heather Kinkead Postdoctoral Fellow, Elizabeth Jaffee Lab , Johns Hopkins School of Medicine


  • Tumors that have previously been classified as low immunogenicity may have neoantigens that can be targeted by neoantigen-specific vaccines, inducing tumor-specific T cells that are not spontaneously induced by the tumor
  • The addition of treatment with antibodies specific for OX40 and PD-1 to neoantigen vaccine results in near complete tumor regression and is protective against tumor rechallenge
  • T cells that have infiltrated the tumor after combined vaccine and checkpoint therapy do not express the exhaustion markers Tim3, Lag3, or PD-1 and maintain neoantigen-specific reactivity up to 2 months post-vaccine



Vaccine Manufacturing

Development of Safe, Efficacious and Cost-Efficient Cancer Neoantigen Vaccines


  • Preclinical proof-of-concept: identification of neoantigens and construction of highly immunogenic and efficacious vaccines
  • Clinical studies: design consideration and execution strategy
  • Cost-efficient GMP-production of personalized neoantigen vaccines

Overcoming Timing and Manufacturing Constraints with Neoantigen Therapy


  • Automating manual steps to improve efficiency of therapy
  • How fast can you define neoantigens, manufacture and provide them in a formulation for patient treatment?
  • Ensuring operational efficiency when scaling up neoantigen personalised therapies to ensure you meet patient demand
  • How rapidly can the therapy be built and disseminated?
  • How to increase turn around times and increase cost effectiveness and how does this relate to safety?

Chairman’s Closing Remarks

Close of Congress